BOCA RATON, Fla, March 03, 2016 -- RxStrategies, Inc. is pleased to announce the appointment of Russell Crane to the new position of Sales Manager - Northeast Region. He joins the RxStrategies’ sales team and has responsibility for sales and delivery of customized 340B pharmacy administration and split billing solutions to providers located in the Northeast Region.
"I am very pleased to welcome Russell to the RxStrategies’ team,” said Fenton Markevich, Chief Executive Officer for RxStrategies. “We look forward to incorporating Russell’s market and product expertise and knowledge for the benefit of our existing and future clients. We believe that Russell will be a strong addition and will complement our current market facing sales and account management teams.”
Russell joins RxStrategies with strong pharmacy industry background, with a particularly strong presence in the Northeast in market facing roles to the pharmacy administration and 340B markets. Russell is a graduate of Northeastern University.
"RxStrategies has a strong reputation in the marketplace with both a unique and transparent processing solution, and a proprietary split billing solution for this complex market," said Crane. "I am excited to join a growing industry leader and bring value to clients and prospects by using a consultative approach. I look forward to continuing that tradition by providing 340B guidance and insight to our current and future clients."
About RxStrategies, Inc.
Established in 2003 and headquartered in Boca Raton, Florida, RxStrategies, Inc. provides accountability, transparency and value-based solutions for the Federal 340B Drug Pricing Programs. As a full-service 340B Drug Pricing Program services organization, RxStrategies provides a diverse range of services to all “Qualified Entities” and the in-house and/or contract pharmacies, including 340B administration, split billing, orphan drug, and audit services. RxStrategies’ “real-time” comprehensive solutions are designed to meet the challenges of regulatory compliance, patient eligibility, pharmacy replenishment, program tracking and reporting of the Federal 340B Drug Pricing Program. To learn more, please visit www.340Bplus.com.
Media Contact: Cheryl Musial, Media Relations, Mopdog, Inc. [email protected] 678-737-7325


Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
OpenAI Explores Massive Funding Round at $750 Billion Valuation
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 



